BXRX - Baudax rises after mid-stage data for neuromuscular blocking agent

2023-03-27 12:09:23 ET

• Nano-cap biotech Baudax Bio ( NASDAQ: BXRX ) ended a six-day losing streak on Monday in reaction to promising data from a Phase 2 trial for its experimental neuromuscular blocking agent BX1000 in patients undergoing elective surgery.
• Citing a second interim analysis of the study, the company said that after receiving BX1000, 41 patients across four cohorts met the criteria for Good or Excellent intubating conditions at 60 seconds.
• Based on a standardized scale, the company considers the percentage of patients meeting the criteria for Good or Excellent intubating conditions as the study's primary endpoint.
• The randomized trial was designed to compare BX1000 at three different dose levels against the neuromuscular blocking agent rocuronium in 80 adult patients who were undergoing elective surgery using total intravenous anesthesia.
• Baudax Bio ( BXRX ) has licensed BX1000 as well as its short-duration blocking agent BX2000 and chemical reversal agent BX3000 from Cornell University.
• Read data from the first interim analysis of the study.

For further details see: